Projekt

Overcoming Resistance to Immunotherapy combining Gemcitabine with atezolizumab in advanced NSCLC and mesothelioma progressINg under immune-checkpoint inhibitors or gemcitabine. A multicenter, single-arm, open label phase II trial with two cohort.

Abgeschlossen · 2021 bis 2024

Jörger Markus, Scherrer Julia, Quinter Janine